- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02678234
An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu
March 9, 2018 updated by: GlaxoSmithKline
An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With Symptoms of an Upper Respiratory Tract Infection
The purpose of the study is to assess the short term efficacy of the Theraflu Aktiv powder for oral solution in the Russian population as compared to an untreated group to support the indication of "Short term relief of the symptoms of colds, chills and influenza, including mild to moderate pain, fever and nasal congestion".
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants must understand and provide written informed consent before any assessment is performed, understand the study procedures, and be willing and able to complete the required assessments
- Males and females ≥ 18 years
- Clinical diagnosis of a URTI as diagnosed by the investigator which would be classified as ICD-10 code J00 (acute nasopharyngitis common cold)
- Mild to moderate sore throat, i.e. rated as 1 or 2 on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3=severe), or headache (1, 2 or 3) or fever (less than 39°C ) or/and Nasal congestion (blocked nose): may be accompanied by rhinorrhea (runny nose) and/or sneezing
- Baseline Jackson TSS > 8
- Common cold symptoms for less than 48 hours
Exclusion Criteria:
- Use of other investigational drugs within 30 days or 5 half-lives of enrollment, whichever is longer. Investigational drug refers to any drug being evaluated in clinical trials
- History of or known hypersensitivity to any of the study drugs, excipients or to drugs of similar chemical classes
- Sacharoze/maltose deficiency, fructose intolerance, glucosegalactose malabsorbtion
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/mL) or urine dipstick at baseline
- Any history of drug hypersensitivity, asthma, urticaria, or other significant allergic diathesis. participants with uncomplicated seasonal allergic rhinitis can be accepted if expected allergy season is clearly one month outside enrollment/ treatment period
- Any history of brain diseases, liver diseases or epilepsy
- Any evidence of uncontrolled cardiovascular (including hypertension), pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinological, metabolic, neurological or psychiatric diseases at screening
- Subject has closed angle glaucoma, urinary retention, prostatic hyperplasia, pyloroduodenal obstruction, pheochromocytoma, diabetes mellitus
- A positive alcohol breath test or positive urine drug screen or a medical history data indicative of alcoholism, drug addiction, or drug abuse within the preceding 2 years
- Subject is current smoker of ≥10 cigarettes per day (or reports equivalent smoking habits using other tobacco products) and is unwilling to refrain from smoking while at the study site
- Subject is current smoker of ≥10 cigarettes per day (or reports equivalent smoking habits using other tobacco products) and is unwilling to refrain from smoking while at the study site
- Subject is taking or has taken within the last two weeks of dosing monoamine oxidase inhibitors, antidepressants, atropine, beta-blocking or sympathomimetic drugs desferrioxamine, hepatotoxic drugs, drugs inducing liver microsomal enzyme, (such as phenytoin, carbamazepine, isoniazid and rifampicin), neuroleptic drugs, chlorzoxazone, CNS depressant drugs including barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics or is anticipated to require any of these medications at any time throughout the study
- Subject has used: Systemic or topical corticosteroids (with the exception of HRT and contraceptive steroids for females), within 3 weeks prior to dosing or Slow-release steroids (with the exception of HRT and contraceptive steroids for females) within 90 days prior to dosing
- Subject has used any of the following medications within 6 hours before first study drug administration, or is anticipated to use any of these medications at any time throughout the study: Any inhaler, medicated confectionary, throat lozenges, throat pastilles, sprays, any products with demulcent properties such as chewing gums and boiled sweets or mints, Any medication for sore throat containing a local anesthetic, Cold products and oral nasal decongestant products, Paracetamol or any NSAID
- Subject has used substances of abuse, herbal medicines, antihistamines and homeopathic medicine within 72 hours of dosing or is anticipated to require any of these drugs at any time throughout the study
- Subject was previously enrolled into the current study
- Persons directly or indirectly involved in the execution of this protocol, including first-degree relative of a study investigator, employees of the clinical study site, employees of the CRO and persons related to them
- "Vulnerable" individual (as defined by the IRB e.g. incarcerated person)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: No Treatment
Participants in this arm will not receive any medication
|
|
Experimental: Theraflu Aktiv powder for oral solution
Participants in this arm will receive a single dose (1 sachet) of Theraflu Aktiv powder for oral solution
|
One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy assessment
Time Frame: Baseline and 3 hours post dosing
|
The severity of common cold symptoms will be self-assessed using the Jackson 8 items scale (questionnaire) by the participants on the site.
This questionnaire measures the severity of 5 local symptoms (nasal congestion, rhinorrhea, sneezing, cough, and sore throat) and 3 systemic symptoms (chilliness, headache, malaise) each on a 4-point ordinal scale (0=not present, 1= mild, 2=moderate, 3= severe).
|
Baseline and 3 hours post dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
February 1, 2017
Primary Completion (Anticipated)
April 1, 2017
Study Completion (Anticipated)
April 1, 2017
Study Registration Dates
First Submitted
February 4, 2016
First Submitted That Met QC Criteria
February 4, 2016
First Posted (Estimate)
February 9, 2016
Study Record Updates
Last Update Posted (Actual)
March 12, 2018
Last Update Submitted That Met QC Criteria
March 9, 2018
Last Verified
March 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Infections
- Respiratory Tract Infections
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antipyretics
- Protective Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Cardiotonic Agents
- Micronutrients
- Respiratory System Agents
- Vitamins
- Antioxidants
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Nasal Decongestants
- Adrenergic alpha-1 Receptor Agonists
- Acetaminophen
- Ascorbic Acid
- Phenylephrine
- Oxymetazoline
Other Study ID Numbers
- 205638
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infections, Respiratory Tract
-
Vakzine Projekt Management GmbHFGK Clinical Research GmbHUnknownInfection, Respiratory TractGermany
-
GlaxoSmithKlineCompletedInfections, Respiratory TractGermany
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractAustralia
-
GlaxoSmithKlineCompletedInfections, Respiratory Tract
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory TractUnited States
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusCanada
-
GlaxoSmithKlineCompletedInfections, Respiratory Syncytial VirusUnited States
Clinical Trials on Paracetamol, phenylephrine HCl, and vitamin C
-
GlaxoSmithKlineWithdrawnInfections, Respiratory Tract
-
University of MinnesotaCompletedEpstein-Barr Virus Infections | Cytomegalovirus Infections | Transplantation InfectionUnited States
-
Shiraz University of Medical SciencesCompletedRestless Legs Syndrome | Kidney Failure, ChronicIran, Islamic Republic of
-
Johnson & Johnson Consumer Inc. (J&JCI)Terminated
-
AronPharma Sp. z o. o.Medical University of Warsaw; Medical University of GdanskCompletedBioavailability of Vitamin CPoland
-
Fudan UniversityRecruitingMetastatic Pancreatic Cancer | Terminal CancerChina
-
University of East AngliaThe Norfolk and Norwich University Hospitals NHS Foundation Trust; The Quadram...Not yet recruiting
-
Damascus UniversityRecruitingDistal Radius Fracture | Prophylaxis | Vitamine cSyrian Arab Republic